KALAMAZOO, Michigan, USA, July 6, 2023 /PRNewswire/ -- Stryker (NYSE:SYK) announced the launch of its Ortho Q Guidance system, the only fully autonomous system in the industry, easily controlled by the surgeon from the sterile field. The system combines new optical tracking options via a redesigned, state-of-the-art camera with sophisticated algorithms of the newly launched Ortho Guidance software to deliver additional surgical planning and guidance capabilities When used with Ortho Q, the Ortho Guidance software for Express Knee, Precision Knee and Versatile Hip serves as a planning and intraoperative guidance system that enhances procedural speed and efficiency through a smart, streamlined workflow.
"Ortho Q was designed specifically for our orthopaedic customers and is the culmination of a multiyear collaboration between teams in India, Germany and the United States. This platform builds a foundation for the future of orthopaedic surgical capability," said Bill Scott, vice president and general manager of Stryker's Orthopaedic Instruments business.
Ortho Q Guidance system features include:
For more information, please visit Stryker's Ortho Q Guidance product page at https://www.stryker.com/us/en/orthopaedic-instruments/c/Ortho-Q-Guidance.html
About Stryker
Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.
Media contact
Hillary Eley
Sr. Manager, Strategic Communications
Instruments
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$328.45 |
Daily Change: | 1.82 0.56 |
Daily Volume: | 1,559,209 |
Market Cap: | US$124.970B |
April 30, 2024 January 31, 2024 January 30, 2024 January 17, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB